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Letter to the Editor 
Sirs, 
We read with great interest the paper by Yamamoto et al. recently published.[1] Of note, 
endoscopy with biopsies is considered as the gold standard for the diagnosis and follow-up of 
patients with inflammatory bowel disease (IBD) but is expensive, time-consuming, and poorly 
accepted by the patient. Detection and follow-up of bowel inflammation may be investigated 
by several plasma and stool biomarkers, especially faecal calprotectin (FC), which might be 
one of the most accurate. 
Different methods and kits for the measurement of FC are commercialised. However, data 
comparing FC concentrations between available methods remain scarce. 
During a period of 7 days, a stool sample was obtained from 26 adult patients, 20 of whom 
were affected by IBD. FC concentrations were assessed at the biochemistry department of 
Rennes hospital, France. Three methods were tested: two ELISA tests [‘Calprest’ from 
Eurospital (dosing range 15–500 μg/g) and ‘Bühlmann fCAL ELISA’ from BÜHLMANN 
(dosing range 30–1800 μg/g)], and one fully automated immunoassay [‘LIAISON 
Calprotectin’ from DiaSorin using chemiluminescent immunoassay on a LIAISON-XL 
Analyser (dosing range 5–800 μg/g)]. Calprotectin extraction from stools was performed 
using the same device. The extraction buffer was provided by each manufacturer. Samples 
with values exceeding the upper limit of linearity were diluted and reanalysed. 
The three different tests were compared using scatter graphs (Figure 1). Bühlmann fCAL 
ELISA and LIAISON Calprotectin were well correlated (Pearson correlation test, r = 0.83, 
P < 0.0001, Figure 1a), whereas Calprest was poorly correlated with LIAISON (Pearson 
correlation test, r = 0.28, P = 0.0062, Figure 1b) as well as with Bühlmann fCAL ELISA 
(Pearson correlation test, r = 0.51, P = 0.0001). This lack of correlation of Calprest test with 
the others may be due, at least in part, to the discrepancy observed for high FC concentrations. 
 
 
Figure 1. (a) Correlation and trendline between the Bühlmann fCAL ELISA and the 
LIAISON Calprotectin assays (r = 0.83, P < 0.0001), and (b) correlation and trendline 
between the LIAISON Calprotectin assay and the Calprest assay (r = 0.28, P = 0.0062). 
In addition, the direct comparison of absolute FC values between the three tests demonstrated 
a poor correspondence. A twofold to threefold increase was observed. FC values obtained 
with the Bühlmann assay were twofold higher compared with the DiaSorin assay and 
threefold higher compared with the Eurospital assay. 
Objective mucosal or transmural inflammation (endoscopy or imaging) was assessed for 15 of 
the 26 patients in the same week. Characteristics of each test were determined to predict 
mucosal inflammation using a FC concentration cut-off of 250 μg/g.[2] The sensibility, 
specificity, positive predictive value, and negative predictive value for Bühlmann fCAL-
ELISA, LIAISON Calprotectin, and Calprest were 73%, 60%, 83% and 43%, 67%, 100%, 
100% and 50%, and 47%, 100%, 100% and 38%, respectively. 
In conclusion, a huge difference was observed between the three FC assays that resulted in 
varying accuracy of FC in predicting mucosal inflammation, according to the method used. 
This result confirms previous report from Havelka et al.[3] When looking for cut-off values of 
FC to manage patients with IBD, these differences should be taken into account. These 
variations make unavoidable the use of the same method during the follow-up of patients and 
point out the urgent need for further standardization or method specific cut-off. 
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